Please use this identifier to cite or link to this item:
Title: Tumour necrosis factor inhibitor-related lupus: safety of switching agents.
Authors: Luong, Jessica M T;Tan, Boon T;Buchanan, Russell R C;Schachna, Lionel
Department of Rheumatology, Austin Health, PO Box 5555, Heidelberg, VIC, 3084, Australia
Issue Date: 2-Feb-2010
Citation: Clinical Rheumatology 2010; 29(5): 551-3
Abstract: An increase in reports of systemic lupus erythematosus (SLE) related to tumour necrosis factor inhibitor (TNFi) therapy has recently been highlighted. We report new-onset SLE in a 22-year-old woman after 13 months of infliximab for ankylosing spondylitis (AS). Lupus symptoms promptly resolved and serologic abnormalities improved after infliximab was ceased. A flare of AS symptoms after 2 months prompted cautious introduction of an alternative TNFi, etanercept. At 14 months follow-up, neither clinical nor serologic flare of lupus had occurred. To our knowledge, this is the third reported case of infliximab-related lupus that did not recur on switching to an alternative TNFi.
Internal ID Number: 20119843
DOI: 10.1007/s10067-009-1365-y
Type: Journal Article
Subjects: Adult
Antibodies, Monoclonal.pharmacology
Antirheumatic Agents.pharmacology
Immunoglobulin G.pharmacology
Lupus Erythematosus, Systemic.blood.drug therapy
Quality of Life
Receptors, Tumor Necrosis Factor
Spondylitis, Ankylosing.blood.drug therapy
Time Factors
Tumor Necrosis Factor-alpha.antagonists & inhibitors
Appears in Collections:Journal articles

Files in This Item:
File SizeFormat 
20119843.pdf43.12 kBAdobe PDFView/Open

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.